1-4 of 4
Angela Hu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 3 Study to Evaluate the Efficacy and Safety of Caplacizumab without First-Line Therapeutic Plasma Exchange in Adults with Immune-Mediated Thrombotic Thrombocytopenic Purpura

Sriya Gunawardena, Angela Hu, Laurel A. Menapace, Hikaru Okada, Beverly Accomando, Julie Lin
Journal: Blood
Blood (2022) 140 (Supplement 1): 2770–2771.
https://doi.org/10.1182/blood-2022-156304
Published: 2022
Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Myelofibrosis Treated with Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in the Randomized, Placebo-Controlled, Phase III JAKARTA Study

Ruben A Mesa, MD, Nicolaas Schaap, MD PhD, Alessandro M Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Francesco Passamonti, MD, Sonja Zweegman, Moshe Talpaz, MD, Srdan Verstovsek, MD PhD, Shelonitda Rose, Derek Tang, PhD BSPharm, Angela Hu, MS, EDM, Carrie Brownstein, MD, Shien Guo, PhD, Xiaomei Ye, MS, Claire N Harrison, Professor
Journal: Blood
Blood (2019) 134 (Supplement_1): 704.
https://doi.org/10.1182/blood-2019-129020
Published: 2019
Journal Articles

Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib

Claire N Harrison, Professor, Nicolaas Schaap, MD PhD, Alessandro M Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Eric Jourdan, MD, Richard T. Silver, MD, Harry C Schouten, MD PhD, Francesco Passamonti, MD, Sonja Zweegman, Moshe Talpaz, MD, Srdan Verstovsek, MD PhD, Shelonitda Rose, Derek Tang, PhD BSPharm, Angela Hu, MS, EDM, Shien Guo, PhD, Weiqin Liao, MS, Carrie Brownstein, MD, Ruben A Mesa, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2207.
https://doi.org/10.1182/blood-2019-129386
Published: 2019
Journal Articles

Expanded Access Program (EAP) for Lenalidomide (Revlimid®) Plus Dexamethasone in over 1400 Subjects with Relapsed or Refractory Multiple Myeloma.

Christine Chen, MD, Donna E. Reece, MD, David Siegel, MD, Ruben Niesvizky, MD, Ralph Vincent Boccia, MD, Edward A. Stadtmauer, MD, Rafat Abonour, MD, David Irwin, MD, Jonathan Polikoff, MD, Shaji Kumar, MD, Richard A. Gams, MD, Laurie Kenvin, RN,BS, Dale McElveen, MBA, Angela Hu, MS, Dennis Pietronigro, PhD, Robert D. Knight, MD, Jerome B. Zeldis, MD,PhD
Journal: Blood
Blood (2006) 108 (11): 3556.
https://doi.org/10.1182/blood.V108.11.3556.3556
Published: 2006